# What UK Biobank Data Suggests About Cannabis, BMI, Diabetes, and Hypertension

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/cannabis-metabolic-health-study-uk-biobank/
> **Published:** 2026-05-11T18:09:00-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:43:21-04:00
> **Clinical Summary:** A UK Biobank cohort of 91,002 adults links cannabis and type 2 diabetes risk, but only below a BMI of 25. What the hazard ratios support, and what they do not.

---

CED Clinical Relevance #73Strong Clinical RelevancePatients with prediabetes, hypertension, or obesity ask whether cannabis helps or hurts their metabolic numbers. This cohort gives a partial answer that depends on body weight, and it demands careful reading because several widely repeated summaries of it overstate what the confidence intervals allow.

A large prospective cohort reports lower incident type 2 diabetes among cannabis users, with the association concentrated in people whose BMI is under 25 and reversing in people whose BMI is over 30. The effect sizes are modest, several confidence intervals sit against the null, and the design cannot establish cause.

Clinical Insight | CED Clinic

Researchers followed 91,002 UK Biobank participants who were free of metabolic disease at baseline and compared incident hypertension, type 2 diabetes, obesity, hyperlipidemia, and non-alcoholic fatty liver disease by cannabis use. Published in *Nutrition, Metabolism and Cardiovascular Diseases* on April 17, 2026, the analysis found an adjusted hazard ratio of 0.82 (95% CI 0.69 to 0.99) for type 2 diabetes.

The more useful finding is not the headline number. It is that the direction of the association changed with body mass index, which means this is a study about patient selection rather than a study about cannabis.

Cannabis and MetabolismType 2 DiabetesBody Mass Index[Endocannabinoid System](https://cedclinic.com/endocannabinoid-system-fear-extinction/)Cohort Evidence
AudiencePatients, caregivers, and cliniciansPrimary TopicCannabis use, body mass index, and incident metabolic diseaseSource[Read the full source](https://doi.org/10.1016/j.numecd.2026.104762)
Why This Matters

Patients with rising A1c values, a new hypertension diagnosis, or a weight trajectory they dislike ask directly whether cannabis is helping or hurting. Until recently the honest answer was that the population data were thin and inconsistent. This cohort is large enough to give a partial answer.

The partial answer is uncomfortable for anyone who wants a single sentence. Cannabis use tracked with lower metabolic risk in leaner participants and with higher risk in participants with obesity. That pattern argues against any general statement about cannabis and metabolic health, and in favor of a conversation that starts with the individual patient’s body.

What the Cohort Actually Reported

The study, *Association between cannabis use and risk of metabolic disease in UK biobank*, was conducted by Shaowen Zhou, Juhui He, Xiaolu Chen, Chee Shin Lee, Lixia Zhang, Ying Hu, and Zhaoxia Liang at Women’s Hospital School of Medicine, Zhejiang University, and Taizhou First People’s Hospital. It appeared in *Nutrition, Metabolism and Cardiovascular Diseases*, volume 36, issue 9, article 104762, published April 17, 2026.

The analytic sample was 91,002 UK Biobank participants with no prevalent metabolic disease at baseline. Multivariable Cox proportional hazards models produced these adjusted hazard ratios for cannabis use: overall metabolic disease 0.94 (95% CI 0.89 to 0.99), hypertension 0.93 (95% CI 0.87 to 1.00), type 2 diabetes 0.82 (95% CI 0.69 to 0.99), and obesity among heavy users 0.57 (95% CI 0.41 to 0.78).

Two of those intervals deserve attention. The hypertension interval reaches 1.00, so that result does not exclude no effect. The type 2 diabetes interval stops at 0.99, which clears the threshold but leaves very little margin. Neither hyperlipidemia nor non-alcoholic fatty liver disease showed a significant association in either direction.

The BMI Interaction Is the Finding That Matters

The authors tested whether body mass index modified the association and found significant interactions at P less than 0.01. Below a BMI of 25, the inverse associations were most evident. Above a BMI of 30, the pattern inverted: moderate cannabis use was associated with an adjusted hazard ratio of 1.26 for overall metabolic disease and 1.40 for hypertension.

An interaction of that size is not a footnote. It means the pooled hazard ratios in the abstract are averages across two populations that behaved differently, and that quoting the pooled number to a patient with obesity misrepresents what the data say about that patient.

It is worth being precise about the subgroup labels. The elevated risk above a BMI of 30 was reported for moderate use, and the 43 percent lower obesity risk was reported for heavy users. Those are different exposure categories, and collapsing them into a single statement about cannabis users is one of the ways this paper has been misreported.

A Plausible Mechanism, and Why It Is Not Proof

There is a coherent endocannabinoid account of why body weight might change the direction of this association. CB1 receptors are expressed in adipose tissue, liver, skeletal muscle, and hypothalamus. In obesity, peripheral endocannabinoid tone is characteristically elevated. Adding an exogenous CB1 agonist to a system already running high is not pharmacologically equivalent to adding one to a system with normal tone.

That story fits the data. Fitting the data is not the same as explaining them. This cohort measured self-reported cannabis exposure and recorded incident diagnoses. It did not measure endocannabinoid tone, receptor density, cannabinoid dose, or product composition, so the mechanism remains a hypothesis that this study is consistent with rather than one it tests.

Readers who want mechanistic human evidence should look to controlled physiology rather than cohort epidemiology. Cohort data can tell you where to point a trial. It cannot substitute for one.

What Is Missing From the Exposure Data

The exposure here is self-reported cannabis use recorded in a UK cohort recruited between 2006 and 2010, during a period when cannabis was illegal in the United Kingdom. Under-reporting in that setting is expected, and it is not random: people who under-report may differ systematically from people who do not.

The dataset also carries no product-level detail. There is no record of THC to CBD ratio, route of administration, dose, or frequency beyond broad use categories. A daily oral CBD-dominant preparation and occasional high-THC inhalation are the same exposure in this analysis, which is a substantial limitation for any clinical translation.

Finally, the UK Biobank is not representative of the UK population. Participants are healthier, wealthier, and less deprived than the general population, which limits how far these hazard ratios travel.

How This Changes a Clinical Conversation

The practical output of this paper is a question, not a recommendation. The question is whether a given patient sits in the part of the distribution where the association was favorable or the part where it was not, and the first input to that question is body mass index.

For a patient with a BMI under 25 who uses cannabis and is worried that it is damaging their metabolic health, this cohort is reassuring at the population level. It is not permission, and it is not evidence of benefit, but it argues against reflexive alarm.

For a patient with a BMI over 30, the honest statement is that the population signal in this dataset ran the other way, that the reason is unknown, and that appetite effects, product choice, and sleep disruption are all plausible contributors worth examining individually. That is a more useful conversation than a verdict.

Study SnapshotStudy TypeProspective cohort, multivariable Cox proportional hazards modelsCohortUK BiobankParticipants91,002 adults with no prevalent metabolic disease at baselineInstitutionsWomen’s Hospital School of Medicine, Zhejiang University; Taizhou First People’s HospitalExposureSelf-reported cannabis use, categorized by frequencyPrimary OutcomesIncident hypertension, type 2 diabetes, obesity, hyperlipidemia, NAFLDKey ResultsOverall metabolic disease aHR 0.94 (0.89 to 0.99); type 2 diabetes aHR 0.82 (0.69 to 0.99); hypertension aHR 0.93 (0.87 to 1.00); obesity, heavy users, aHR 0.57 (0.41 to 0.78)Effect ModificationSignificant BMI interaction, P less than 0.01. Above BMI 30, moderate use aHR 1.26 for metabolic disease and 1.40 for hypertensionNull FindingsNo significant association for hyperlipidemia or non-alcoholic fatty liver diseaseJournalNutrition, Metabolism and Cardiovascular Diseases, 2026;36(9):104762PMID / DOI42115075 / 10.1016/j.numecd.2026.104762
How Strong Is This Evidence?

This is a well-powered observational cohort, which places it above cross-sectional surveys and below randomized trials. The UK Biobank supports long follow-up and adjusted modeling, and 91,002 participants is enough to detect the modest effect sizes reported here. For the question of whether a population-level association exists, the design is adequate.

For the question of whether cannabis changes metabolic risk, the design cannot deliver. Cannabis users in this cohort differ from non-users in ways no model fully captures, including diet, activity, alcohol, sleep, and health-seeking behavior. The authors themselves conclude that the findings should be interpreted cautiously given the observational design.

Where This Paper Deserves Skepticism

The hypertension confidence interval reaches 1.00. A result whose interval includes the null should not be described as a reduction in hypertension risk, and several summaries of this paper have done exactly that. The type 2 diabetes interval stops at 0.99, which is statistically significant by convention but fragile enough that a modest change in modeling choices could move it.

Self-reported cannabis use collected in a jurisdiction where cannabis was illegal invites differential misclassification. The heavy-use obesity result, an adjusted hazard ratio of 0.57, is the largest effect in the paper and also the one most exposed to reverse causation, since body weight influences who becomes and stays a heavy user as readily as the reverse.

What This Paper Does Not Show

This cohort does not show that cannabis prevents type 2 diabetes, lowers blood pressure, or treats metabolic disease. It reports associations between a self-reported exposure and incident diagnoses in a non-representative volunteer cohort.

It also identifies no product, dose, ratio, route, or timing. Nothing in this dataset supports recommending a cannabis preparation for metabolic indications, and nothing in it establishes which patients would benefit if such an effect existed.

How This Fits With the Broader Clinical Conversation

The result sits alongside a consistent epidemiological pattern in which cannabis users show lower average body mass index and lower diabetes prevalence than non-users, despite reporting higher caloric intake. That pattern has been reported often enough to be taken seriously as an observation and has never been explained well enough to be taken seriously as a mechanism.

What this cohort adds is the effect modification by body weight. Previous work treated cannabis users as one group. Splitting them by BMI produced opposite signs, which suggests the field has been averaging across populations that do not belong in the same estimate.

Dr. Caplan’s Take

I read this paper twice, and the second reading was more useful than the first. The headline everyone repeated was that cannabis lowers diabetes and hypertension risk. The hypertension interval touches 1.00. That is not a finding, and repeating it as one does patients a disservice.

What I do take from it is the BMI interaction, because it matches something I see. In leaner patients, cannabis rarely disturbs metabolic numbers in either direction. In patients carrying significant weight, the variable that most often matters is not the cannabinoid at all. It is what happens two hours after a high-THC evening dose, and whether the patient is eating through it. That is a modifiable problem, and it is the conversation this paper should be starting.

I would not change a single patient’s plan on the basis of a hazard ratio of 0.82 from a volunteer cohort. I would use this to justify asking better questions at the visit.

Clinical Bottom Line

In 91,002 UK Biobank adults, cannabis use was associated with modestly lower incident type 2 diabetes and overall metabolic disease, with the association concentrated below a BMI of 25 and reversed above a BMI of 30. Treat the direction as hypothesis-generating, treat body mass index as the variable that changes the conversation, and do not present any of it to a patient as evidence of benefit.

What a Careful Reader Should Take Away

Carry forward the interaction, not the pooled estimate. The useful sentence is that the relationship between cannabis use and metabolic risk in this cohort depended on body weight. The sentence to leave behind is that cannabis lowers hypertension risk, because the confidence interval for that outcome does not support the claim.

Evidence Interpretation Guide

Table of Contents

- [How to read a hazard ratio without overselling it](#How_to_read_a_hazard_ratio_without_overselling_it)
- [Cannabis, Diabetes, and Body Weight, Seen From Eight Angles](#Cannabis_Diabetes_and_Body_Weight_Seen_From_Eight_Angles)[Your body weight changes the answer](#Your_body_weight_changes_the_answer)
- [Use it to change the questions, not the plan](#Use_it_to_change_the_questions_not_the_plan)
- [Two intervals are doing a lot of work](#Two_intervals_are_doing_a_lot_of_work)
- [The exposure is the weak link](#The_exposure_is_the_weak_link)
- [The new part is the interaction](#The_new_part_is_the_interaction)
- [What actually moves metabolic numbers](#What_actually_moves_metabolic_numbers)
- [What would actually answer this](#What_would_actually_answer_this)
- [Why the reporting matters](#Why_the_reporting_matters)
- [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related)

## How to read a hazard ratio without overselling it

The Research QuestionIs cannabis use associated with incident metabolic disease in a large prospective cohort, and does body mass index modify that association?The Patient QuestionI have prediabetes or high blood pressure and I use cannabis. Is that making things worse?The Bottom LineCannabis use tracked with modestly lower incident type 2 diabetes in this cohort, mainly among leaner participants, and with higher risk among participants with obesity. The study describes a pattern. It does not establish a cause or support a treatment.
CED Perspective Lens

## Cannabis, Diabetes, and Body Weight, Seen From Eight Angles

One large cohort, read through the lenses that matter at the bedside.

Lens OverviewAmong 91,002 UK Biobank adults, cannabis use was associated with lower incident type 2 diabetes overall, with the association evident below a BMI of 25 and reversed above a BMI of 30.

#### Your body weight changes the answer

If you use cannabis and your BMI is under 25, this cohort found no signal that it is raising your risk of diabetes or high blood pressure, and a modest signal in the other direction. That is reassurance about population averages, not proof of benefit for you.

If your BMI is over 30, the same study found the opposite pattern for moderate use. The reason is unknown. It could be appetite, product choice, sleep disruption, or something the researchers could not measure, and those are worth looking at one at a time with your physician.

Lens takeawayBring your actual numbers to the visit. This is a study where the answer depends on which patient is asking.

#### Use it to change the questions, not the plan

The effect sizes here do not support altering management. An adjusted hazard ratio of 0.82 from a volunteer cohort with self-reported exposure is not a therapeutic signal. What it does justify is asking cannabis-using patients with metabolic risk about timing, route, evening dosing, and food intake after use.

The interaction term is the clinically actionable part. It tells you that a single statement about cannabis and metabolic risk will be wrong for roughly half your panel.

Lens takeawayStratify the conversation by body mass index before offering any generalization.

#### Two intervals are doing a lot of work

The hypertension adjusted hazard ratio is 0.93 with an upper bound of 1.00. By the ordinary convention that is a null result, and yet it has been widely summarized as a 7 percent reduction. The type 2 diabetes upper bound of 0.99 is only marginally better.

Cohort analyses with many outcomes and many models invite fragile findings. The obesity result among heavy users, with a hazard ratio of 0.57, is large enough to warrant suspicion of reverse causation rather than enthusiasm.

Lens takeawayQuote the intervals, not the point estimates, and the paper reads far more cautiously.

#### The exposure is the weak link

Cannabis use was self-reported in a cohort recruited when cannabis was illegal in the United Kingdom. There is no product data, no dose, no THC to CBD ratio, and no route of administration. Everything downstream of that measurement inherits its imprecision.

The UK Biobank is also a volunteer cohort that is healthier and less deprived than the general population, which constrains external validity independent of any cannabis question.

Lens takeawayA precise hazard ratio built on an imprecise exposure is precise about the wrong thing.

#### The new part is the interaction

Population datasets have repeatedly shown lower body mass index and lower diabetes prevalence among cannabis users, a pattern that has resisted explanation for more than a decade. Treating it as a single effect has not moved the field forward.

By testing effect modification by body mass index and finding opposite directions on either side, this analysis suggests earlier pooled estimates were averaging across groups that should have been analyzed separately.

Lens takeawayThe contribution is stratification, not the discovery of an association.

#### What actually moves metabolic numbers

In practice, the cannabis variables most likely to affect a patient’s glucose and weight trajectory are behavioral rather than receptor-level: late-evening high-THC dosing, appetite stimulation during a window when the kitchen is open, and sleep fragmentation at higher doses.

Each of those is addressable without stopping cannabis. Shifting the dose earlier, lowering it, or moving to a preparation with a different cannabinoid balance are all reasonable experiments to run one at a time.

Lens takeawayAdjust timing, dose, and route before drawing conclusions about the molecule.

#### What would actually answer this

The field needs prospective studies with objectively characterized products, recorded doses, and metabolic endpoints measured directly rather than extracted from diagnostic codes. Controlled physiology, including glucose clamp work, answers mechanistic questions that cohorts cannot.

Stratified enrollment by baseline body mass index should be built into those designs from the start, given the interaction reported here.

Lens takeawayDefine the product, measure the dose, and stratify by body weight before the first patient enrolls.

#### Why the reporting matters

This paper was summarized in places as showing that cannabis reduces hypertension and diabetes risk. The hypertension interval does not support that, and the diabetes result is modest and observational. Overstated coverage of metabolic benefit is the kind of claim that later gets used to discredit the entire field.

Accurate reporting of confidence intervals is not pedantry in cannabis medicine. It is the difference between a field that earns clinical trust and one that spends it.

Lens takeawayThe credibility cost of overstating this result is higher than any gain from the headline.
Related Reading at CED ClinicContinue exploring the evidence[Cannabis and Metabolism: The Hidden Connection](https://cedclinic.com/cannabis-and-metabolism/)

Background on how cannabinoids intersect with body weight, lipids, and glucose handling.

[Read the overview](https://cedclinic.com/cannabis-and-metabolism/)[High-THC Cannabis Increased Inflammation Without Improving Insulin Sensitivity](https://cedclinic.com/high-thc-cannabis-increased-inflammation-without-improving-insulin-sensitivity/)

A controlled human trial that points the opposite way from the cohort signal, and why both can be true.

[See the trial data](https://cedclinic.com/high-thc-cannabis-increased-inflammation-without-improving-insulin-sensitivity/)[Cannabis and Blood Sugar: What the Evidence Shows](https://cedclinic.com/cannabis-blood-sugar-levels-what-the-evidence-shows-for-wellness-and-balance/)

A practical summary of what is and is not established about cannabinoids and glucose control.

[Review the evidence](https://cedclinic.com/cannabis-blood-sugar-levels-what-the-evidence-shows-for-wellness-and-balance/)

Join the Conversation

Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan)

Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/)

## Frequently Asked Questions

Does cannabis lower the risk of type 2 diabetes?

A UK Biobank cohort of 91,002 adults reported an adjusted hazard ratio of 0.82 for incident type 2 diabetes among cannabis users, with a 95 percent confidence interval of 0.69 to 0.99. That is a statistical association in observational data, not evidence that cannabis prevents diabetes. The study design cannot separate cannabis from the many other ways cannabis users differ from non-users, and the authors state the findings should be interpreted cautiously.

Did the study find that cannabis lowers blood pressure?

No. The adjusted hazard ratio for incident hypertension was 0.93 with a 95 percent confidence interval of 0.87 to 1.00. Because that interval reaches 1.00, the result does not exclude the possibility of no effect. Summaries describing this as a 7 percent reduction in hypertension risk overstate what the data support. Hypertension should be treated as a null finding in this cohort.

Why does body mass index change the results?

The researchers tested whether BMI modified the association and found significant interactions at P less than 0.01. Below a BMI of 25, the inverse associations were most evident. Above a BMI of 30, moderate cannabis use was associated with higher risk, with adjusted hazard ratios of 1.26 for overall metabolic disease and 1.40 for hypertension. The cohort does not explain why the direction reversed.

What about cholesterol and fatty liver disease?

Neither outcome showed a significant association in either direction. The analysis included incident hyperlipidemia and non-alcoholic fatty liver disease alongside hypertension, type 2 diabetes, and obesity, and reported null results for those two. That matters because selective reporting of the favorable outcomes gives a misleading picture of a paper that found a mixed set of results.

How large was the obesity finding?

Among heavy cannabis users, the adjusted hazard ratio for incident obesity was 0.57 with a 95 percent confidence interval of 0.41 to 0.78. That is the largest effect in the paper. It is also the result most exposed to reverse causation, because body weight plausibly influences who becomes and remains a heavy cannabis user rather than only the other way around.

Does this study say anything about CBD or specific products?

No. The UK Biobank recorded self-reported cannabis use without product detail. There is no information on THC to CBD ratio, dose, route of administration, or preparation. A daily oral CBD-dominant product and occasional high-THC inhalation are indistinguishable in this dataset, which is a major limitation for translating the results into any product recommendation.

Should a patient with prediabetes change their cannabis use based on this?

Not on the basis of this study alone. The effect sizes are modest, the design is observational, and the exposure data lack product and dose detail. A more productive response is to examine the behavioral variables that plausibly affect glucose and weight: timing of dosing, evening use, appetite effects, and sleep quality. Those can be adjusted individually and assessed against actual laboratory values.

Where was this study published and who conducted it?

It appeared in Nutrition, Metabolism and Cardiovascular Diseases, volume 36, issue 9, article 104762, published April 17, 2026. The authors are Shaowen Zhou, Juhui He, Xiaolu Chen, Chee Shin Lee, Lixia Zhang, Ying Hu, and Zhaoxia Liang, based at Women’s Hospital School of Medicine, Zhejiang University, and Taizhou First People’s Hospital. The PubMed identifier is 42115075.

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).